Baker Brothers Advisors - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 161 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$11,261,000
+15.9%
673,9080.0%0.05%
-16.7%
Q1 2020$9,718,000
-56.9%
673,9080.0%0.06%
-50.0%
Q4 2019$22,556,000
+59.8%
673,9080.0%0.12%
+25.0%
Q3 2019$14,112,000
+0.6%
673,9080.0%0.10%
+1.1%
Q2 2019$14,031,000
-6.8%
673,9080.0%0.10%
-1.0%
Q1 2019$15,062,000
-6.6%
673,9080.0%0.10%
-27.3%
Q4 2018$16,120,000
-12.3%
673,9080.0%0.13%
+9.1%
Q3 2018$18,384,000
+1.5%
673,9080.0%0.12%
-11.0%
Q2 2018$18,121,000
-15.5%
673,9080.0%0.14%
-25.3%
Q1 2018$21,450,000
-15.8%
673,9080.0%0.18%
-17.6%
Q4 2017$25,487,000
+52.6%
673,9080.0%0.22%
+63.7%
Q3 2017$16,706,000
+20.6%
673,9080.0%0.14%
+11.6%
Q2 2017$13,856,000
-5.4%
673,9080.0%0.12%
+0.8%
Q1 2017$14,644,000
+6.3%
673,9080.0%0.12%
-11.1%
Q4 2016$13,781,000
+36.3%
673,9080.0%0.14%
+46.7%
Q3 2016$10,109,000
+38.6%
673,9080.0%0.09%
+21.1%
Q2 2016$7,292,000
+115.1%
673,908
+169.6%
0.08%
+111.1%
Q1 2016$3,390,000
-26.5%
250,0000.0%0.04%
-5.3%
Q4 2015$4,613,000
-27.1%
250,0000.0%0.04%
-34.5%
Q3 2015$6,330,000250,0000.06%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 414,500$14,280,00013.67%
Burrage Capital Management LLC 332,546$11,456,0009.04%
Penn Mutual Asset Management, LLC 158,783$5,470,0007.72%
First Trust Capital Management L.P. 525,598$18,107,0004.87%
GARDNER LEWIS ASSET MANAGEMENT L P 653,711$22,520,0004.08%
ALPINE ASSOCIATES MANAGEMENT INC. 2,075,100$71,488,0003.76%
S. MUOIO & CO. LLC 90,000$3,101,0003.52%
EQUITEC PROPRIETARY MARKETS, LLC 124,700$4,296,0003.27%
GABELLI & Co INVESTMENT ADVISERS, INC. 501,719$17,284,0003.11%
WATER ISLAND CAPITAL LLC 1,062,245$36,594,0003.11%
View complete list of AIMMUNE THERAPEUTICS INC shareholders